Name | Value |
---|---|
Revenues | 28.0K |
Cost of Revenue | -41.6K |
Gross Profit | 69.6K |
Operating Expense | 1,616.9K |
Operating I/L | -1,547.3K |
Other Income/Expense | -178.6K |
Interest Income | 150.7K |
Pretax | -1,576.3K |
Income Tax Expense | -177.7K |
Net Income/Loss | -1,576.3K |
OpGen, Inc. is a precision medicine company specializing in molecular microbiology solutions. The company's product portfolio includes in vitro diagnostic tests for detecting bacterial nucleic acids and genetic determinants of antimicrobial resistance, as well as polymerase chain reaction-based SARS-CoV-2 test kits. OpGen also offers an automated sample-to-answer molecular diagnostics platform that integrates sample preparation, analysis, and identification of disease-relevant pathogens and antibiotic resistance markers. The company generates revenue by commercializing these molecular microbiology solutions, providing clinicians with information about infectious diseases, and collaborating with healthcare institutions to detect, track, and manage antimicrobial-resistant infections.